New drug combo aims to boost surgery success in bile duct cancer
NCT ID NCT07267078
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can improve outcomes for people with bile duct or gallbladder cancer. About 45 adults with resectable or borderline-resectable cancer will receive 2-4 cycles of the combination, then undergo surgery. Researchers will check if the treatment leads to cleaner surgical margins, deeper tumor shrinkage, and longer survival without major side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tuvonralimab and Iparomlimab (immunotherapy drugs) combined with gemcitabine-oxaliplatin chemotherapy
- What this could lead to
- If successful, this could lead to a new treatment option that helps more patients with biliary tract cancer have successful surgery and live longer without the cancer returning.
- What could go wrong
- This is a small, early-phase trial with only 45 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects, and the combination may not improve outcomes enough to change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?